Incremento de supervivencia en melanoma - page 8

•

Pre-planned significance p < 0.01

•

No statistical significance

Pembrolizumab post-Ipi in melanoma:

Keynote 002-Primary Endpoints

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7 9,10,11,12,13,14,15,16,17,18,...29